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INTRODUCTION
Marked advances in the diagnosis and treatment
of hepatocellular carcinoma (HCC) have prolonged
survival. However, recurrent HCC and the exacer-
bation of liver cirrhosis, an underlying disease, re-
quire frequent admissions, leading to prolonged ad-
mission for many patients (1, 2). In HCC treatment,
if the hospitalization period could be shortened, a
significant improvement might result in patient qual-
ity of life.
In 2003, Diagnosis Procedure Combination (DPC)
was introduced for specific hospitals, and will be ap-
plied throughout Japan. Shortening of the hospitali-
zation period is emphasized as an important issue
for hospital management. Clinical path procedures
have been introduced in an increasing number of
hospitals to reduce the hospitalization period.
In the field of HCC treatment, clinical paths for
transcatheter arterial embolization (TAE), radio fre-
quency ablation (RFA), and resection have been in-
troduced in an increasing number of hospitals. How-
ever, in many patients with HCC, treatment is not
selected on admission ; in most hospitals, therapeu-
tics strategies are determined after hematology and
imaging procedures such as abdominal angiography
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and computed tomography (CT) under angiography
are performed after admission. This allows for the
detailed examination of the HCC status and back-
ground hepatic reserve. As well, treatments for HCC
vary : transarterial procedures such as TAE, percu-
taneous procedures such as percutaneous ethanol
infusion (PEI), resection, and liver transplantation. In
some patients, treatment is not completed by a sin-
gle therapy. There appears to be no consensus re-
garding treatment selection. The recent develop-
ment of new equipment such as the Interventional-
Radiology computed-tomography/angio system (IVR-
CT system) (3), which facilitates the simultaneous
accomplishment of CT and serial angiography, and
procedures including RFA, is changing diagnostic
and treatment procedures.
Several studies have reported hospitalization times
for a single therapy such as RFA and TAE, but no
study has investigated it for HCC treatment as a
whole. Here, we examine changes in the time from
admission until discharge in HCC patients, the rea-
sons for changes in time, tumor state/treatment-
related differences and hepatic reserve. We also in-
vestigate whether the new diagnostic IVR-CT system
and a new treatment procedure, RFA, shortens the
hospitalization period. As well, we reviewed whether
the future introduction of clinical path procedures
would further shorten the interval.
PATIENTS AND METHODS
The subjects were 346 patients with HCC who un-
derwent internal medicine treatment because of dif-
ficulties or refusal related to surgical treatment be-
tween January 1991 and March 2002 (total : 486 ad-
missions). Patients were divided into 2 groups (early
and late phase groups) by the time of treatment, be-
fore and after September 1999, when the IVR-CT
system and RFA were introduced. With respect to
treatment, they were divided into 4 groups : a TAE
group in which transarterial procedures such as se-
lective transcatheter arterial embolization (s-TAE)
were performed ; a PEI group in which PEI was per-
formed ; a TAE+PEI group in which PEI was addi-
tionally performed due to the less marked local cura-
tive effects of a transarterial approach, or PEI was
additionally performed to treat HCC in another site
following a transarterial approach ; and a RFA group
in which RFA was performed. We also investigated
the hospitalization period with respect to hepatic re-
serve (Child-Pugh classification), tumor factors in-
cluding the number of tumors and maximum tumor
diameter. In patients with advanced HCC (stage
-A), which requires long-term admission, we in-
vestigated the hospitalization period with respect
to treatment procedures and hepatic reserve. For
tumor staging we used the general rules for the clini-
cal and pathological study of primary liver cancer (4).
In patients in whom varix treatment was concur-
rently performed, we reviewed the period during
which they were admitted to treat HCC. We ex-
cluded patients with extrahepatic metastasis, as sys-
temic chemotherapy and radiotherapy targeted an-
other lesion other than HCC.
In selecting treatment, CT under portography and
CT under hepatic arteriography (CTHA) were per-
formed (5, 6). When the entire tumor was stained on
CTHA, a transarterial treatment such as s-TAE was
selected. About 2 weeks after treatment, we evalu-
ated the treatment response. When there were less
marked local curative effects, PEI or transarterial
treatment was additionally performed. Treatment was
continued in accordance with the hepatic reserve
until complete necrosis was achieved. We also se-
lected PEI or RFA for patients in whom tumors were
not stained on CTHA, and those in whom marked
flexion and narrowing of the hepatic artery made it
difficult to selectively insert a catheter into the seg-
mental/subsegmental vessels. PEI was performed
twice a week if possible. The choice of treatment for
patients with advanced HCC (stage Ⅳ-A) was de-
termined by a similar procedure.
For treatment, tumor factors including the number
of tumors and tumor diameter were not limited. How-
ever, treatment was discontinued in patients in whom
improvement in the prognosis was considered dif-
ficult. In patients with a poor hepatic reserve, adju-
vant therapy was performed prior to treatment to
improve their hepatic conditions.
In this study, all patients who underwent transar-
terial procedures such as conventional TAE via the
hepatic artery, s-TAE, and chemolipiodolization were
assigned to the TAE group. In this group, patients
who underwent s-TAE accounted for approximately
70%, followed by chemolipiodolization, and conven-
tional TAE. In the TAE+PEI group, PEI was addi-
tionally performed in 66 patients, as complete ne-
crosis was not achieved despite transarterial treat-
ment for large tumors. In the other 40 patients, PEI
was performed to treat another lesion.
The hospitalization period was expressed as the
mean±standard deviation. Significance was tested
between 2 groups using Mann-Whitney’s U-test. Val-
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ues were compared among several groups using the
Kruskal-Wallis test. When there was a significant dif-
ference, Bonferroni’s test was employed. A p value
was less than 0.05 (p<0.05 ) was regarded as sig-
nificant. These tests were conducted using Stat View
4.5 software (SAS Institute Inc., U.S.A.).
RESULTS
The early phase group consisted of 205 patients.
The total frequency of admission was 283 times (in-
itial treatment : 157 patients, relapse treatment : 126).
The late phase group consisted of 141 patients. The
total frequency of admission was 203 times (initial
treatment : 98 patients, relapse treatment : 105). Pa-
tient background, tumor type, treatment procedures,
and treatment responses are summarized in Table
1. In our patients with HCC who were treated dur-
ing the study period (10 years), the 1-year, 5-year,
and 10-year survival rates were 85.6%, 31.2%, and
11.9%, respectively. As shown in Fig. 1, the early
phase group was compared with the late phase one.
The mean hospitalization period in HCC late phase
patients (41.0 days) was significantly shorter than
that in early phase ones (58.9 days). In the PEI
group, the mean times were 45.9 and 41.4 days in
the early and late phases, respectively. In the TAE
group, the mean times were 61.8 and 36.7 days in
the early and late phases, respectively. In the TAE
+PEI group, the mean times were 81.0 and 53.5
days in the early and late phases, respectively. In
the TAE group and TAE+PEI group, the mean time
was significantly shorter in the late phase than in
the early.
The hospitalization period in each treatment group
with respect to maximum tumor diameter is shown
in Table 2. In the PEI group, the mean times in the
early and late phases in patients with tumors meas-
uring 3 cm or less were 46.3 and 39.3 days, respec-
tively. In those with tumors measuring 3 to 5 cm,
there were no changes. In those with tumors meas-
uring 5 cm or more, the mean interval was prolonged
from 49.0 to 78.3 days. In the TAE group, the mean
hospitalization period was shortened regardless of
the tumor diameter. There was a significant differ-
ence between the early phase and late phase groups
in patients with tumors measuring 3 to 5 cm. In the
RFA group, the mean times were 25.2 and 20.9 days
in patients with tumors measuring 3 cm or less and
Table 1. Patient background
Early phase group Late phase group
Number of patients 205 141
Frequency of admission 283 203
Age (mean age) 43～87(65.1) 49～83(68.3) p<0.001
Gender Male 188 135 ns
Female 95 68
Hepatic reserve A 49 78 p<0.001
Child-Pugh classification B 146 84
C 88 41
Number of tumors 1 151 108 ns
2 60 38
3 23 22
Many 49 35
Maximum tumor diameter (cm) 3 or less 200 140 ns
3 to 5 48 43
5 or more 35 20
Tumor Stage Ⅰ 75 54 ns
Ⅱ 67 62
Ⅲ 45 27
Ⅳ-A 96 60
Treatment PEI 125 76 p<0.0001
TAE 97 63
TAE+PEI 61 45
RFA 0 19
Treatment response Complete necrosis 196 154 ns
Incomplete necrosis 87 49
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those with tumors measuring 3 to 5 cm, respectively.
In the TAE+PEI group, the mean hospitalization pe-
riod was shortened for all tumor diameters. This ten-
dency was more marked in patients with larger tu-
mors. There were significant differences between
the early and late phase groups in those patients
with tumors measuring 5 cm or more.
The hospitalization period in each treatment group
with respect to number of tumors is shown in Table
3. In the PEI group, the mean interval was short-
ened in patients with 2 tumors or with 4 or more
tumors. However, there was no shortening in those
with 1 or 3 tumors. In the TAE group, the mean hos-
pitalization period was shortened regardless of the
tumor number. There was a significant difference
between the early phase and late phase groups in
patients with 3 tumors. In the RFA group, the mean
times were 20.9 and 38.0 days in patients with a
single lesion and those with 2 lesions, respectively.
In the TAE+PEI group, the mean time was short-
ened in most groups. However, it was prolonged
in those patients with 3 lesions.
Concerning the hepatic reserve, the times were
42.3±27.8 days in Child-Pugh A patients, 53.8±41.0
Fig. 1 Hospitalization period in the early and late phase groups
The hospitalization period was expressed as the mean±standard deviation. In the PEI group, the mean time were 45.9 and 41.4 days
in the early and late phases, respectively, with no significant difference. In the TAE group and the TAE+PEI group, the mean time in
the late phase was significantly shorter than that in the early phase.
Table 2. Hospitalization period in each treatment group with respect to maximum tumor diameter
～3 3～5 5～ (cm)
PEI Early phase 46.3±34.1(111)
ns
42.0±19.8(12)
ns
49.0±26.9(2)
ns
group Late phase 39.3±24.7(63) 43.7±18.5(10) 78.3±48.4(3)
TAE Early phase 59.8±54.0(59)
＊
60.0±40.4(20)
ns
70.3±34.7(18)
＊
group Late phase 33.6±17.3(41) 42.6±24.6(14) 42.8±19.5(8)
RFA Early phase ー ー ー
group Late phase 25.2±28.0(12) 20.9±8.6(7) ー
TAE+PEI Early phase 76.6±50.2(30)
ns
85.6±53.0(16)
ns
89.5±29.7(15)
＊
group Late phase 53.5±20.7(24) 54.2±17.0(12) 52.7±17.9(9)
＊p<0.05
The hospitalization period was expressed as the mean±standard deviation.
A number in a parenthesis shows the number of patients.
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days in Child-Pugh B patients, and 56.3±38.0 days
in Child-Pugh C patients ; the mean time was shorter
in patients with a better hepatic reserve, and there
was a significant difference between Child-Pugh A
and B groups, and between Child-Pugh A and C
groups. Among Child-Pugh A patients, the mean
times were 43.6±36.9 and 37.8±19.5 days in the
early and late phase groups, respectively. Among
Child-Pugh B patients, the values were 60.6±46.1
and 41.8±26.4 days, respectively. Among Child-Pugh
C patients, the values were 61.5±42.1 and 45.2±24.3
days, respectively. In all patients in late phase groups
the mean interval was shortened. In Child-Pugh B
patients, there was a significant difference between
the early phase and late phase groups.
In the early phase, 64 patients with stage Ⅳ-A
HCC were treated, with a total frequency of admis-
sion of 96. In the late phase, 39 stage Ⅳ-A patients
were treated, with a total frequency of admission
of 60. The incidence of solitary lesions was higher
in the early phase group, possibly because many
patients showed portal invasion (Table 4). In stage
Ⅳ-A patients, the early and late phase groups, the
mean times were 67.1 and 50.0 days, respectively,
showing a significant difference. For treatment pro-
cedures, mean times were shortened in all groups.
However, in the PEI group, there was no significant
difference between the early and late phase groups
(Fig. 2). In respect to hepatic reserve, the times
were 47.0±26.2 days in Child-Pugh A patients, 61.0
Table 3. Hospitalization period in each treatment group with respect to number of tumors
1 2 3 Many
PEI Early phase 41.7±31.0(89)
ns
48.7±24.1(21)
ns
67.6±52.6(7)
ns
66.3±42.4(8)
ns
group Late phase 39.1±26.6(48) 32.9±11.8(15) 65.9±24.7(10) 37.7±10.8(3)
TAE Early phase 59.2±56.3(46)
＊
58.4±37.3(17)
＊
74.8±45.4(6)
ns
65.4±40.7(28)
＊
group Late phase 33.1±19.3(29) 31.4±18.8(8) 56.6±24.7(5) 39.0±18.8(21)
RFA Early phase ー ー ー ー
group Late phase 20.9±21.4(16) 38.0±27.5(3) ー ー
TAE+PEI Early phase 83.2±41.2(16)
＊
87.2±50.0(22)
ns
54.6±26.6(10)
ns
88.3±51.8(13)
ns
group Late phase 46.5±16.3(15) 55.7±22.6(12) 60.4±19.9(7) 56.2±16.3(11)
*p<0.05
The hospitalization period was expressed as the mean±standard deviation.
A number in a parenthesis shows the number of patients.
Table 4. Background factors of stage Ⅳ-A patients
Early phase group Late phase group
Number of patients 64 39
Frequency of admission 96 60
Age (mean age) 43～83(64.8) 49～82(68.9) p<0.001
Gender Male 62 38 ns
Female 34 22
Hepatic reserve A 11 20 p=0.14
Child-Pugh classification B 51 25
C 34 15
Number of tumors 1 11 2 ns
2 27 17
3 17 13
Many 41 28
Maximum tumor diameter (cm) 3 or less 53 33 ns
3 to 5 22 14
5 or more 21 13
Treatment PEI 24 14 ns
TAE 40 25
TAE+PEI 32 20
RFA 0 1
Treatment response Complete necrosis 35 28 ns
Incomplete necrosis 61 32
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±39.4 in Child-Pugh B patients, and 68.4±35.5 in
Child-Pugh C patients ; the mean time was shorter
in patients with a better hepatic reserve, and there
was a significant difference between the Child-Pugh
A and C groups. Among Child-Pugh A patients, the
times were 53.6±36.9 and 43.6±18.1 days in the
early and late phase groups, respectively. Among
Child-Pugh B patients, the values were 67.2±45.0
and 48.3±19.2 days, respectively. Among Child-Pugh
C patients, the values were 71.3±38.7 and 61.8±26.9
days, respectively. In all late phase groups, the mean
time was significantly shortened.
DISCUSSION
Sackett, et al. reported that it was important to
follow 5 steps of problem extraction, information in-
vestigation, critical review, performance, and evalu-
ation, for preparing a clinical path based on the EBM
(7). This study corresponds to the first step (prob-
lem extraction), and we investigated the hospitali-
zation times required for HCC treatment and its
limitations.
In our PEI group, the hospitalization period saw
no further reduction after 1997. With respect to tu-
mor diameter, the interval was prolonged in patients
with tumors measuring 3 cm or more. From this ex-
amination, PEI may not be a preferred method for
treating large tumors. The infusion dose per shot
was increased, and several punctures per session
were performed. However, these strategies did not
markedly contribute to any shortening of the hospi-
talization period. PEI was developed by Sugiura, et al.
in 1983(8). Since then, a multiple-needle insertion
technique (9) and a CT-assistance method have been
reported. However, basically, neither instruments
nor procedures have improved since ; thus there was
no marked decrease in the hospitalization period. In
essence, PEI may have been developed as a com-
plete procedure that can not be further improved
and so it is unlikely that any marked shortening of
the hospitalization period will be seen in the future.
Indeed, RFA may be the method mainly employed
for percutaneous treatment. However, PEI may still
be applicable for treating small tumors and those ad-
jacent to other organs, the bile duct, and blood ves-
sels. Strategies for shortening the hospitalization pe-
riod must be established.
TAE was initially reported by Yamada, et al. in
1983(10). Since then, Segmental Lipiodol-TAE has
been developed (11). The interval was markedly
Fig. 2 Stage Ⅳ-A patients : Hospitalization period in the early and late phase groups
The hospitalization period was expressed as the mean±standard deviation. For treatment procedures, mean times were shortened
in all groups. However, in the PEI group, there was no significant difference between the early and late phase groups
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shortened after 1998, that is, before the IVR-CT sys-
tem was introduced. This was possibly because new
devices such as a selective guide-wire and flexible
catheter were developed in 1998 (12), and intro-
duced in our department. The IVR-CT system may
have contributed to a decrease in the hospitalization
period between 1998 and 1999. The appearance of
these new devices including the IVR-CT system has
facilitated TAE via the cancer-bearing artery and
multi-segmental TAE in which TAE is simultane-
ously performed via several responsible blood ves-
sels (13, 14). Complete necrosis of the lesion has in-
creasingly been achieved by a single course of TAE
even in patients with large HCC lesions, and those
with multiple lesions.
RFA facilitates more extensive ablation per course
compared to microwave ablation therapy. It more ac-
curately achieves tumor necrosis compared to PEI
(15), and is now being introduced in many hospitals.
In some hospitals, a clinical path has been estab-
lished, and the hospitalization period shortened to
1 week or less. Recently, some studies have reported
that RFA prolongs survival in comparison with PEI
(16, 17). In an increasing number of hospitals, RFA
has been selected as a first-choice percutaneous treat-
ment. As well, several studies have established an
extensive area of ablation for large HCC lesions to
enable ablation to be completed by a single course
of RFA (18, 19). RFA will be mainly employed as the
percutaneous treatment in the future.
In TAE+PEI therapy, the addition of PEI is per-
formed to treat intra-capsular/extra-capsular infil-
tration and that immediately below the capsule or
around the septum, for which TAE alone is less ef-
fective (20-22). In this group, the proportion of pa-
tients with advanced tumors in whom it was diffi-
cult to continue treatment until complete necrosis
was achieved was higher than those in the other
groups. We treated only HCC lesions that might rup-
ture, and the minimum treatment for improving the
prognosis was initially planned for early discharge,
which may have contributed to a marked decrease.
With respect to tumor factors, the interval was pro-
longed in patients with 3 tumors. This patient group
showed the highest tumor count among those for
which complete necrosis can be targeted, 1 to 3, and
so treatment targeting complete necrosis may have
prolonged the time.
TAE and TAE+PEI were performed in 45% and
32%, respectively, of Stage Ⅳ-A patients ; many were
treated by transarterial procedures. Complete ne-
crosis was achieved in 71% of HCC patients ; how-
ever, it was achieved in only 38% of Stage Ⅳ-A pa-
tients. In Stage Ⅳ-A patients, the length of hospi-
talization was about 20% longer than that in the HCC
patients. However, over the past 10 years it has been
shortened to approximately 60%.
The hospitalization period was shorter in patients
with a better hepatic reserve. This was because treat-
ment per course was limited in those with a poor
hepatic reserve, increasing the frequency of treat-
ment and prolonging the treatment interval. Even
in patients with a poor hepatic reserve, the accurate
treatment-related reduction of the grade of disorders
of the normal liver tissue shortened the hospitaliza-
tion period.
Issues that are not directly related to medical prac-
tice may also influence the hospitalization period :
the bed-waiting interval until examination is not con-
stant ; and the intervals between examination and
treatment, between treatment and response evalu-
ation, and between response evaluation and discharge
are not efficiently established. To overcome such
limitations, a system to establish clinical paths needs
to be established. For TAE, patients are admitted the
day before angiography, and the lesion site is pho-
tographed using the IVR-CT system after the end of
treatment. When sufficient treatment has been ac-
complished, patients are discharged 7 to 10 days af-
ter treatment. Treatment response is evaluated at
the outpatient clinic. For PEI, patients are admit-
ted the day before angiography, and percutaneous
treatment is performed the day after angiography.
On Days 3, 7, and 11, treatment is performed. On
Days 10, 14, and 18, the treatment response is evalu-
ated. Even when 3 courses of treatment are per-
formed, patients may be discharged approximately
20 days after admission. For RFA, treatment is per-
formed on Day 3, and the treatment response is
evaluated on Day 6, as described for PEI. Treatment
for TAE+PEI, is similarly performed. However, the
interval between TAE and the initial course of PEI
is established as 2 weeks, and PEI is performed on
Days 16, 20, and 24. The treatment response is evalu-
ated on Days 23, 27, and 31. Even when PEI is added
3 times, treatment is completed within 1 month of
admission. If possible, RFA should be selected as
an additional therapy.
When a clinical path is prepared as described
above, the hospitalization period is 10 to 20 days
for PEI, about 1 week for TAE and RFA, and 3 to 4
weeks for TAE+PEI. However, in our study, the in-
tervals were 41.4, 36.7, 23.6, and 53.5 days, respec-
tively, in the late phase group. This was because our
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series included many patients requiring additional
treatments, those with severe hepatopathy after treat-
ment, and those with complications (23-25). When
establishing a clinical path, these patients may be
dropped as variances. Standard deviations were 17.6,
20.6, 16.3, and 26.6 days in the TAE, PEI, TAE+PEI
and RFA groups, respectively. They clearly decreased
year by year. However, there were still marked dif-
ferences. Thirty-eight episodes in the early and 5 epi-
sodes in late phase groups required more than a 100-
day period for admission. Seventeen episodes were
for patients with TAE+PEI and 15 episodes were pa-
tients with TAE in the early phase group, and one
was a patient with TAE+PEI in the late phase group.
The situation where hepatic failure appeared after
treatment, and where hospitalization continued to
next treatment was the majority one. It may be re-
alistic to undertake examination and treatment in an-
other hospitalization, and for patients in TAE+PEI
group to be discharge in the interim between TAE
and PEI. In preparing a clinical path, the above is-
sues need to be considered. For a hospitalization
practice for HCC, strategies must be established to
shorten the length of the hospitalization. As well, is-
sues should be reviewed at the next step by intro-
ducing a clinical path. If a standard clinical path is
finally prepared, it would have benefits for HCC pa-
tients and for the medical professionals charged with
hospital management.
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